9 results about "Fenofibrate" patented technology

A fenofibrate composition comprising water soluble chemicals, the composition having a higher dissolution rate in an aqueous medium, wherein the composition is prepared by mixing fenofibrate in an organic solvent solution with an organic acid and other excipients to produce the composition in the form of granules, a tablet or a capsule.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

The invention belongs to the technical field of drug crystallization, and provides metformin hydrochloride and fenofibrate double-drug-loading particles and a preparation method thereof.The preparation method comprises the following steps that polysaccharide, a solvent I and metformin hydrochloride are mixed and heated, and a homogeneous solution is obtained; mixing the homogeneous solution, fenofibrate and triglyceride to obtain a suspension; a cross-linking agent, a solvent II and the suspension are mixed and placed in a crystallizer to be subjected to a crystallization reaction, and a crystallization solution is obtained; and carrying out solid-liquid separation on the crystallization liquid, washing, and drying to obtain the double-drug-loading particles. The obtained particles are in a solid state and have good stability compared with a micelle drug loading system, meanwhile, the operation unit is simplified by adopting an in-situ crystallization means in the carrier, operation such as mixing, grinding and spray drying is not needed, needed equipment is simple, operation is easy and convenient, and good technical economy and high application value are achieved.

The invention provides a composition and method of treating depression by administering to a patient in need of such treatment a combination of pindolol and fenofibrate in a ratio of about 3mg pindolol / 33mg fenofibrate and is useful in augmentation to treatment of depression.

The invention provides a double-layer tablet containing ezetimibe and fenofibrate. The double-layer tablet comprises an ezetimibe quick release layer and a fenofibrate slow release layer, the ezetimibe quick-release layer comprises ezetimibe, a quick-release layer filler, a quick-release layer surfactant, a quick-release layer adhesive, a quick-release layer disintegrating agent and a quick-release layer lubricant; the fenofibrate sustained-release layer comprises fenofibrate, a sustained-release layer filler, a sustained-release layer disintegrating agent, a sustained-release layer adhesive, a sustained-release layer solubilizer, a sustained-release layer sustained-release framework material and a sustained-release layer lubricant. The invention also provides a preparation method of the double-layer tablet. The double-layer tablet provided by the invention can be used for clinical treatment of hypercholesterolemia, hypertriglyceridemia and mixed dyslipidemia, the levels of triglyceride, total cholesterol and LDL-C are comprehensively reduced, the level of HDL-C is increased, and the occurrence rate of adverse reactions is relatively low.

The invention discloses application of fenofibrate in preparation of a medicine for preventing obesity or renal ischemia-reperfusion injury aggravated by high fat diet induction, and relates to the technical field of medicines. The invention relates to an application of fenofibrate in preparation of a medicine for preventing renal ischemia reperfusion injury aggravated by obesity or high fat diet induction. The prophylaxis potential of fenofibrate is verified in an obesity and common mouse renal ischemia reperfusion injury (IRI) model for the first time, and a means for effectively inhibiting obesity-induced injury aggravation is lacked in the treatment of kidney IRI at present, especially under the background of high fat diet or metabolic stress. The fenofibrate relieves injury aggravation caused by high fat / obesity, and a new preventive drug choice is provided for the field. According to the invention, a preventive scheme of starting administration in advance is adopted, which shows that intervention of fenofibrate on the early stage of IRI occurrence also can effectively reduce the risk of subsequent injury, which has a reference value for'preoperative administration 'or'intervention of obese high-risk patients' in clinic.

This invention belongs to the field of pharmaceutical technology and discloses a pharmaceutical composition of a USP7 inhibitor and fenofibrate and its antitumor application. The pharmaceutical composition uses a USP7 inhibitor and fenofibrate as the core active ingredients, with a molar ratio of 0.015625 to 0.625. The USP7 inhibitor is selected from at least one of LX04-104 and LML-17-133. This invention is the first to discover that fenofibrate can significantly enhance the antitumor effect of the USP7 inhibitor, and the combination of the two has a synergistic effect. This synergistic effect is cell type specific, particularly significant for nasopharyngeal carcinoma and pancreatic cancer, and the synergistic effect of fenofibrate is independent of the PPARα pathway. This composition can be prepared as an oral or injectable formulation for the treatment of nasopharyngeal carcinoma and pancreatic cancer, and has good prospects for clinical translation.

The invention relates to a fenofibrate nano eutectic composition and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The fenofibrate nano eutectic composition is composed of fenofibrate, a eutectic forming agent, a stabilizer, a filler, a flow aid and a lubricant. The specific method comprises the following steps: forming a fenofibrate eutectic from fenofibrate and a eutectic forming agent, and performing nanocrystallization through a medium grinding method so as to improve the solubility and the dissolution rate of an indissolvable bulk drug; forming a nano suspension from the nano-crystallized eutectic, a stabilizer and water, and freeze-drying to obtain stable nano eutectic particles; and uniformly mixing with other auxiliary materials, and filling into capsules or pressing into tablets. Compared with an original drug, the dissolution rate and bioavailability of the tablet are increased.